Year All20242023202220212020201920182017201620152014 Abivax and Scripps Research Announce FDA Approval to Initiate a Phase 1/2 Clinical Trial with ABX196 in Patients with Hepatocellular Carcinoma May 13, 2019 Read More Abivax Receives First Phase 2b Ulcerative Colitis Clinical Trial Authorization, Provides Update on Progress of ABX464 Clinical Development Plan in Inflammatory Diseases April 30, 2019 Read More Abivax 2018 Financial Results and Operations Update March 14, 2019 Read More Abivax Presents Impressive New Phase 2a ABX464 Ulcerative Colitis 6-Months Maintenance Study Data in Oral Plenary Session at Annual Congress of European Crohn’s and Colitis Organisation (ECCO) March 11, 2019 Read More Abivax Chosen to Deliver ABX464 Oral Presentation at Digestive Disease Week (DDW) Conference in the U.S. March 05, 2019 Read More Abivax to Present Latest Clinical and Mechanism of Action Data on its Lead Compound ABX464 at Two Upcoming Conferences February 22, 2019 Read More Abivax Publishes in Nature Scientific Reports ABX464's Unique Mechanism of Action Leading to Both Anti-Inflammatory and Antiviral Effects January 28, 2019 Read More Abivax Hosts KOL Event in Geneva on Therapeutic Candidate ABX464 for Ulcerative Colitis January 23, 2019 Read More Abivax’s phase 2a ulcerative colitis clinical trial data selected for oral plenary presentation at 14th Congress of European Crohn’s and Colitis Organisation December 20, 2018 Read More Abivax receives DSMB recommendation to continue ongoing extension study of its completed phase 2a clinical trial in ulcerative colitis patients December 06, 2018 Read More
Abivax and Scripps Research Announce FDA Approval to Initiate a Phase 1/2 Clinical Trial with ABX196 in Patients with Hepatocellular Carcinoma May 13, 2019 Read More
Abivax Receives First Phase 2b Ulcerative Colitis Clinical Trial Authorization, Provides Update on Progress of ABX464 Clinical Development Plan in Inflammatory Diseases April 30, 2019 Read More
Abivax Presents Impressive New Phase 2a ABX464 Ulcerative Colitis 6-Months Maintenance Study Data in Oral Plenary Session at Annual Congress of European Crohn’s and Colitis Organisation (ECCO) March 11, 2019 Read More
Abivax Chosen to Deliver ABX464 Oral Presentation at Digestive Disease Week (DDW) Conference in the U.S. March 05, 2019 Read More
Abivax to Present Latest Clinical and Mechanism of Action Data on its Lead Compound ABX464 at Two Upcoming Conferences February 22, 2019 Read More
Abivax Publishes in Nature Scientific Reports ABX464's Unique Mechanism of Action Leading to Both Anti-Inflammatory and Antiviral Effects January 28, 2019 Read More
Abivax Hosts KOL Event in Geneva on Therapeutic Candidate ABX464 for Ulcerative Colitis January 23, 2019 Read More
Abivax’s phase 2a ulcerative colitis clinical trial data selected for oral plenary presentation at 14th Congress of European Crohn’s and Colitis Organisation December 20, 2018 Read More
Abivax receives DSMB recommendation to continue ongoing extension study of its completed phase 2a clinical trial in ulcerative colitis patients December 06, 2018 Read More
